Bard to Allow Endologix Option to Expire.Business Editors/Health & Medical Writers MURRAY HILL, N.J.--(BW HealthWire)--Dec. 14, 2000 C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc. (NYSE NYSE See: New York Stock Exchange :BCR), today announced that it will not exercise its option to acquire the remaining capital stock of Endologix, Inc., a California-based company involved in the development of endoluminal grafts used for the minimally invasive treatment of abdominal aortic aneurysms. Bard will continue in its role as exclusive distributor for Endologix's product in Europe and Australia. "We remain committed to our goal of leadership in the treatment of peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. ," said William H. Longfield, Bard's Chairman and Chief Executive Officer. "While the Endologix AAA AAA: see American Automobile Association. (Triple A) A common single-cell battery used in a myriad of electronic devices of all variety. Like its double A (AA) cousin, it provides 1.5 volts of DC power. When used in series, the voltage is multiplied. device continues to show promise, considerable time and expense will still be necessary to develop this market. We do not believe this opportunity warrants the significant investment required under the option agreement," Longfield concluded. The company expects to take a fourth quarter charge associated with this decision. C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill, New Jersey
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion